Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group.

Abstract

The aim of this study was to learn the toxicity and efficacy of adding 4 doses of rituximab to a standard platinum-based salvage regimen for relapsed CD20+ B-cell non-Hodgkin lymphoma. Patients were treated with rituximab 375 mg/m(2) days 1,8,15, 22 (cycle 1 only); cisplatin 100 mg/m(2) over 24 h on day 3, cytosine arabinoside 2 g/m(2) IV every 12 h x two doses on day 4, dexamethasone 40 mg PO/IV days 3-6, and G-CSF days 5-14. The ORR was 82% (47/57) with 33% (19/57) complete remissions and 49% (28/57) partial remissions. The duration of response (DR) for the 47 responders was 10.5 months (95% CI: 5.3-16.8). The median time to progression (TTP) was 10.3 months (95% CI: 5.3-14.0), the median event-free survival (EFS) was 5.3 months (95% CI: 3.9-11.0), and the median overall survival was 30.5 months (95% CI: 17.8-60.6). We conclude that rituximab can be safely added to standard DHAP.

• Authors: Thomas E Witzig, Susan M Geyer, Paul J Kurtin, Joseph P Colgan, David J Inwards, Ivana N M Micallef, Betsy R LaPlant, John C Michalak, Muhammad Salim, Robert J Dalton, Dennis F Moore Jr, Craig B Reeder, North Central Cancer Treatment Group
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 49 Issue 6 Pg. 1074-80 (Jun 2008) ISSN: 1029-2403 [Electronic] United States
• PMID: 18569634 (Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Cytarabine
• Rituximab
• Dexamethasone
• Cisplatin

Topics

• Aged
• Aged, 80 and over
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cisplatin (therapeutic use)
• Cytarabine (therapeutic use)
• Dexamethasone (therapeutic use)
• Female
• Humans
• Lymphoma, B-Cell, Marginal Zone (drug therapy)
• Lymphoma, Follicular (drug therapy)
• Lymphoma, Large B-Cell, Diffuse (drug therapy)
• Lymphoma, Mantle-Cell (drug therapy)
• Lymphoma, Non-Hodgkin (drug therapy)
• Male
• Maximum Tolerated Dose
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy)
• Prognosis
• Rituximab
• Salvage Therapy
• Treatment Outcome